Genflow Biosciences Plc an emerging leader in the field of longevity research, focused on developing therapeutic solutions for the prevention of age-related diseases is pleased to announce that all resolutions proposed at the Annual General Meeting held earlier were duly passed.
LONDON, UNITED KINGDOM / ACCESSWIRE / June 27, 2024 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) (“Genflow” or “the Company”) an emerging leader in the field of longevity research, focused on developing therapeutic solutions for the prevention of age-related diseases is pleased to announce that all resolutions proposed at the Annual General Meeting held earlier today were duly passed.
| Contacts Genflow Biosciences | Harbor Access |
| Dr Eric Leire, CEO | Jonathan Paterson, Investor Relations |
| +32-477-495-881 | +1 475 477 9401 |
| Capital Plus Partners Ltd | |
| Keith Swann, +44 0203 821 6169 | |
| Jon Critchley, +44 0203 821 6168 | |
About Genflow
Founded in 2020, Genflow Biosciences Plc. (LSE:GENF)(OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow’s lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Scheduled to begin in 2025, Genflow’s clinical trial aims to explore the potential benefits of GF-1002 in treating MASH (Metabolic Dysfunction-Associated Steatohepatitis), the most prevalent chronic liver disease for which there is no effective treatments.
Please visit www.genflowbio.com and follow the Company on LinkedIn and Twitter/X.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: Genflow Biosciences PLC
View the original press release on accesswire.com
